Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients

References

• Alter CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AK, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389: 856–860
   PubMedGoogle Scholar
• Buckley P, Pilai A, Evans D, Stirewait E, Mahadik S. Brain derived neurotrophic factor in first-episode psychosis. Schizophr Res 2007; 91: 1–5
   PubMed Web of Science ®Google Scholar
• Durany N, Micheal T, Zochling R, Boissl K, Cruz-Sanchez F, Riederer P, et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001; 52: 79–86
   PubMed Web of Science ®Google Scholar
• Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007; 420: 45–48
   PubMed Web of Science ®Google Scholar
• Guillain O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioral sensitization. Nature 2001; 411: 86–89
   PubMedGoogle Scholar
• Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007; 41: 31–35
   PubMed Web of Science ®Google Scholar
• Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000; 95: 2514–2522
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshhimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007; 22: 21–27
   PubMed Web of Science ®Google Scholar
• Jockers-Scherubl MC, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, Schurer F, et al. Brain-derived neurotrophic factor serum concentrations are increased in drug-naïve schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 2004; 371: 79–83
   PubMed Web of Science ®Google Scholar
• Krieger K, Klimke A, Henning U. Antipsychotic drugs influence transport of the beta-adrenergic antagonist [3H]-dihydroalprenol into neuronal blood cells. World J Biol Psychiatry 2004; 5: 100–106
   PubMed Web of Science ®Google Scholar
• Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and noradrenaline release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 1998; 136: 153–161
   PubMedGoogle Scholar
• Lommatzsch M, Zingler D, Schuhbaeck K, Schuhbaeck K, Schloetcke K, Zingler C, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005; 26: 115–123
   PubMed Web of Science ®Google Scholar
• Maas JW, Hattox SE, Green NM, Landis DH. 3-Methoxy-4-hydroxyphenethyleneylglycol production by human brain in vivo. Science 1979; 205: 1025–1027
   PubMed Web of Science ®Google Scholar
• Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, Ramanujam S, et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 2007; 68: 512–517
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Stahl SM. Thee dopamine hypothesis of schizophrenia: a review. Schizophr Bull 1976; 2: 19–76
   PubMed Web of Science ®Google Scholar
• Minegishi A, Ishizaki T. Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric determination. J Chromatogr 1984; 311: 51–57
   PubMed Web of Science ®Google Scholar
• Nagaoka S, Iwamoto N, Arai H. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical response to haloperidol treatment. Biol Psychiatry 1997; 41: 857–864
   PubMedGoogle Scholar
• Pirildar S, Gonul AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Progr Neuro-Psychopharmacol Biol Psychiatry 2004; 28: 709–713
   PubMed Web of Science ®Google Scholar
• Podusto JF, Curran GL. Permeability at the blood-brain and blood nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Mol Brain Res 1996; 36: 280–286
   PubMedGoogle Scholar
• Shimuzu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakari C, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70–75
   PubMedGoogle Scholar
• Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 1976; 133: 197–202
   PubMed Web of Science ®Google Scholar
• Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000; 5: 293–300
   PubMed Web of Science ®Google Scholar
• Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. Deceased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005; 382: 27–32
   PubMed Web of Science ®Google Scholar
• Thoenen H. Neurotrophins and neuronal plasticity. Science 1995; 270: 593–598
   PubMed Web of Science ®Google Scholar
• Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2000; 110: 249–257
   Google Scholar
• Umene W, Yoshimura R, Hori H, Nakano H, Sugita A, Shimono M, et al. Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea. World J Biol Psychiatry 2007; 26: 1–4
   Google Scholar
• Weickert CS, Hyde TM, Lopska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8: 592–610
   PubMed Web of Science ®Google Scholar
• Weickert CS, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, Herman MM, et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2005; 10: 637–650
   PubMed Web of Science ®Google Scholar
• Westerink BHC, De Boer P, Vries JB, Kruse GG, Long SK. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 1998; 361: 27–33
   PubMedGoogle Scholar
• Yamamoto K, Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 913–922
   PubMed Web of Science ®Google Scholar
• Yeung PK, Buckley SJ, Pedder SC, Dingemanse J. Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci 1996; 85: 451–453
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Yanagihara N, Hara K, Terao T, Nakamura J, Ueno S, et al. Inhibitory effects of clozapine and antipsychotic drugs on noradrenaline transporter in cultured bovine adrenal medullary cells. Psychopharmacology 2000a; 149: 17–23
   PubMedGoogle Scholar
• Yoshimura R, Nakamura J, Ueda N, Terao T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels and clinical improvement. Int Clin Psychopharmacol 2000b; 15: 175–180
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Ueda N, Shinkai K, Nakamura J. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 2003; 18: 107–111
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Nakamura J, Shinkai K, Ueda N. Clinical response to antidepressants treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 611–616
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Shinkai K, Toyohira Y, Ueno S, Yanagihara N, Nakamura J. Effects of zotepine and olanzapine on noradrenaline transporter in cultured bovine adrenal medullary cells. Hum Psychopharmacol 2005; 20: 477–484
   PubMedGoogle Scholar
• Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, et al. Treatment with risperidone increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1072–1077
   PubMed Web of Science ®Google Scholar